Barinthus Biotherapeutics (BRNS) Other Non Operating Income (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Other Non Operating Income came in at $39000.0 in Q1 2026, down 48.0% YoY from $75000.0 in Q1 2025, and up 137.5% on a QoQ basis from -$104000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Other Non Operating Income (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Other Non Operating Income data on file, last reported at $39000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 48.0% year-over-year to $39000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20000.0 (down 109.52% YoY) and the FY2025 annual result came in at $16000.0, down 88.15% from the prior year.
- Other Non Operating Income improved to $39000.0 in Q1 2026, from -$104000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $13.8 million in Q1 2022 to a low of -$275000.0 in Q3 2025.
- A 5-year average of $1.1 million and a median of $63000.0 in 2022 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income surged 1800.0% — and 2025, when it sank 1157.69%.
- Tracing BRNS's Other Non Operating Income over 5 years: stood at $516000.0 in 2022, then jumped by 50.0% to $774000.0 in 2023, then sank by 88.5% to $89000.0 in 2024, then sank by 216.85% to -$104000.0 in 2025, then jumped by 137.5% to $39000.0 in 2026.
- The last three Other Non Operating Income figures came in at $39000.0 (Q1 2026), -$104000.0 (Q4 2025), and -$275000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26,000.00 |
| Mar 31, 2026 | 39,000.00 |
| Dec 31, 2025 | -104,000.00 |
| Sep 30, 2025 | -275,000.00 |
| Jun 30, 2025 | 320,000.00 |
| Mar 31, 2025 | 75,000.00 |
| Dec 31, 2024 | 89,000.00 |
| Sep 30, 2024 | 26,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Dec 31, 2023 | 774,000.00 |
| Sep 30, 2023 | -2,000.00 |
| Jun 30, 2023 | 310,000.00 |
| Dec 31, 2022 | 516,000.00 |
| Jun 30, 2022 | 51,000.00 |
| Mar 31, 2022 | 13.79 Mn |
| Sep 30, 2021 | -13.79 Mn |
| Jun 30, 2021 | -3,000.00 |
| Mar 31, 2021 | -13.79 Mn |
| Dec 31, 2020 | -534,000.00 |
| Sep 30, 2020 | 3,000.00 |